CN6 - COST-EFFECTIVENESS MODEL OF MIDOSTAURIN (MIDO) VERSUS...

CN6 - COST-EFFECTIVENESS MODEL OF MIDOSTAURIN (MIDO) VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH NEWLY DIAGNOSED FLT3 MUTATION-POSITIVE (FLT3+) ACUTE MYELOID LEUKEMIA (AML): A FRENCH PERSPECTIVE

Cariou, C., Tremblay, G., Dolph, M., Brandt, P.S., Forsythe, A.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
21
Journal:
Value in Health
DOI:
10.1016/j.jval.2018.09.023
Date:
October, 2018
File:
PDF, 639 KB
2018
Conversion to is in progress
Conversion to is failed